van der Velde K Joeri, Kuiper Joël, Thompson Bryony A, Plazzer John-Paul, van Valkenhoef Gert, de Haan Mark, Jongbloed Jan D H, Wijmenga Cisca, de Koning Tom J, Abbott Kristin M, Sinke Richard, Spurdle Amanda B, Macrae Finlay, Genuardi Maurizio, Sijmons Rolf H, Swertz Morris A
Genomics Coordination Center, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Department of Genetics, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Hum Mutat. 2015 Jul;36(7):712-9. doi: 10.1002/humu.22798. Epub 2015 May 20.
Next-generation sequencing in clinical diagnostics is providing valuable genomic variant data, which can be used to support healthcare decisions. In silico tools to predict pathogenicity are crucial to assess such variants and we have evaluated a new tool, Combined Annotation Dependent Depletion (CADD), and its classification of gene variants in Lynch syndrome by using a set of 2,210 DNA mismatch repair gene variants. These had already been classified by experts from InSiGHT's Variant Interpretation Committee. Overall, we found CADD scores do predict pathogenicity (Spearman's ρ = 0.595, P < 0.001). However, we discovered 31 major discrepancies between the InSiGHT classification and the CADD scores; these were explained in favor of the expert classification using population allele frequencies, cosegregation analyses, disease association studies, or a second-tier test. Of 751 variants that could not be clinically classified by InSiGHT, CADD indicated that 47 variants were worth further study to confirm their putative pathogenicity. We demonstrate CADD is valuable in prioritizing variants in clinically relevant genes for further assessment by expert classification teams.
临床诊断中的下一代测序技术正在提供有价值的基因组变异数据,这些数据可用于支持医疗决策。预测致病性的计算机工具对于评估此类变异至关重要,我们评估了一种新工具——联合注释依赖损耗(CADD),并通过使用一组2210个DNA错配修复基因变异来评估其对林奇综合征基因变异的分类。这些变异已经由国际遗传性结直肠癌小组(InSiGHT)变异解读委员会的专家进行了分类。总体而言,我们发现CADD评分确实能够预测致病性(斯皮尔曼相关系数ρ = 0.595,P < 0.001)。然而,我们发现InSiGHT分类与CADD评分之间存在31个主要差异;通过使用群体等位基因频率、共分离分析、疾病关联研究或二线检测,这些差异得到了解释,支持专家分类。在InSiGHT无法进行临床分类的751个变异中,CADD表明有47个变异值得进一步研究以确认其假定的致病性。我们证明CADD在为临床相关基因中的变异进行优先级排序以供专家分类团队进一步评估方面具有价值。